[NMusers] DDMoRe workshop at PAGE meeting

From: Cheung, Amy <Amy.Cheung_at_astrazeneca.com>
Date: Mon, 22 Feb 2016 18:48:59 +0000

DDMoRe will present a free one day workshop on the 7th of June entitled

"Get inspired ... get started ... get into the world of DDMoRe".
This workshop will consist of presentations and hands-on session with DDMoR=
e products and runs from 9:00 to 18:00 PM:

9:00 - 9:15 General introduction
9:15 - 9:45 Interoperability Framework introduction
9:45 - 10:15 Intro to Model Description Language (MDL)

coffee break

10:30 - 11:00 MDL continued
11:00 - 12:00 Interoperability Framework hands-on session
12:00 - 12:30 Exchange standards

Lunch

13:30 - 14:00 Model Repository, Qualification procedure and Annotations
14:00 - 15:00 Encoding models hands-on session

coffee break

15:15 - 16:45 Model Repository: browse / explore / download / use models
16:45 - 17:15 Introduction to workflow plus new tools
17:15 - 18:00 DDMoRe Foundation: What is the future for DDMoRe? Q&A

All these products together deliver the DDMoRe platform, which will be demo=
nstrated live with real model examples, showing the different elements and =
intended workflows. The added value of the products to efficiently apply mo=
del-based approaches and knowledge exchange - supporting the concept Model =
Informed Drug Discovery and Development (MID3) - will be discussed in the c=
losing session of the workshop.

If you are interested please register to the workshop:

http://www.eventbrite.nl/e/ddmore-workshop-at-page-meeting-2016-registratio=
n-21005999510?ref=ebtn

For more information:

http://www.ddmore.eu/events/page-meeting-lisboa-portugal

________________________________

AstraZeneca UK Limited is a company incorporated in England and Wales with =
registered number: 03674842 and a registered office at 2 Kingdom Street, Lo=
ndon, W2 6BD.

Confidentiality Notice: This message is private and may contain confidentia=
l, proprietary and legally privileged information. If you have received thi=
s message in error, please notify us and remove it from your system and not=
e that you must not copy, distribute or take any action in reliance on it. =
Any unauthorised use or disclosure of the contents of this message is not p=
ermitted and may be unlawful.

Disclaimer: Email messages may be subject to delays, interception, non-deli=
very and unauthorised alterations. Therefore, information expressed in this=
 message is not given or endorsed by AstraZeneca UK Limited unless otherwis=
e notified by an authorised representative independent of this message. No =
contractual relationship is created by this message by any person unless sp=
ecifically indicated by agreement in writing other than email.

Monitoring: AstraZeneca UK Limited may monitor email traffic data and conte=
nt for the purposes of the prevention and detection of crime, ensuring the =
security of our computer systems and checking compliance with our Code of C=
onduct and policies.

Received on Mon Feb 22 2016 - 13:48:59 EST

This archive was generated by hypermail 2.3.0 : Fri Sep 27 2019 - 16:49:09 EDT